A multinational, phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer

Administered By

Awarded By

Contributors

Start/End

  • October 1, 2014 - September 30, 2022